AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Snipd AI
Robin Feldman, an expert in drug patents and generics from the University of California Hastings College of Law, discusses the tactics employed by pharmaceutical companies to reduce competition from generic drugs. Topics include the Hatch-Waxman Act, weak patents, pay for delay settlements, evasion of price controls, complexities of drug pricing, and challenges in replacing branded drugs with ineffective capsules.
Read more
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Pharmaceutical companies employ tactics to reduce competition from generic drugs, leading to higher prices for consumers.
- Citizen petitions are being exploited by pharmaceutical companies to delay entry of generic drugs, highlighting the need for transparency and oversight.
Deep dives
The Complexity of the Pharmaceutical Patent System
The speaker discusses the complexities of the pharmaceutical patent system, where drug companies often employ tactics such as pay-for-delay and evergreening to extend their market exclusivity. These tactics hinder the entry of generic drugs into the market, leading to higher prices for consumers. The speaker argues for the need to simplify the system and create better alignment between the goals of society and the incentives of pharmaceutical companies.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode